Search - tctmd.com

Displaying 301 - 320 of 378

Sort: Relevancy | Date

Presentation TCT 2014

Drug Eluting Stents Versus Coronary Artery Bypass Graft surgery for Isolated Proximal Left Anterior Descending Artery Stenosis: A Meta-analysis

Presenter: Alok Saurav

September 16, 2014

Presentation TCT 2014

Delayed coverage of drug eluting stents after interventional revascularization of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry

Presenter: Christian Heeger

September 16, 2014

Presentation TCT 2014

Two-Year Clinical Outcome of Patients With Implantation of Second-Generation Drug-Eluting Stents in the Right Coronary Ostium in the TWENTE Trial

Presenter: Ming Kai Lam

September 16, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

Presenter: Kazuyuki Yahagi

September 16, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

Bare Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Emmanouil S. Brilakis, J. Dawn Abbott

September 13, 2014

Presentation ESC 2014

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

Presenter: Christoph Varenhorst

August 30, 2014

Presentation Fellows 2014

Drug-Eluting Stents: Past, Present, and Future

Presenter: Gregg Stone

April 12, 2014

Presentation ACC 2014

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Presenter: Masahiro Natsuaki

March 31, 2014

Presentation CTO 2014

Left Main Restenosis: Incidence, Implications, and Management

Presenter: Roxana Mehran

March 01, 2014

Presentation CTO 2014

Dedicated Bifurcation Stents in Left Main Disease: Do the Data Support Their Need?

Presenter: Martin B. Leon

March 01, 2014

Presentation CTO 2014

Bioresorbable Scaffolds in Left Main PCI: Technique Considerations and Outcomes

Presenter: Antonio Colombo

March 01, 2014

Presentation CTO 2014

Are There Meaningful Differences Between Metallic DES in Left Main PCI?

Presenter: Philippe Généreux

March 01, 2014

Presentation TCT 2013

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Presenter: George Dangas

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

Presenter: Ankit Garg

October 29, 2013

Presentation TCT 2013

TCT-50. Angiographic Predictor of 2-Year Stent Thrombosis in Patients Receiving Drug-eluting Stents: Insights from the ADAPT-DES Study

Presenter: Philippe Généreux

October 29, 2013

Presentation TCT 2013

Biodegradable-Polymer Drug-Eluting Stents versus Bare Metal Stents versus Durable-Polymer Drug-Eluting Stents : A Systematic Review and Bayesian Approach Network Meta-Analysis

Presenter: Si-Hyuck Kang

October 29, 2013

Advertisement

Drug Eluting Stents Versus Coronary Artery Bypass Graft surgery for Isolated Proximal Left Anterior Descending Artery Stenosis: A Meta-analysis

Delayed coverage of drug eluting stents after interventional revascularization of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry

Two-Year Clinical Outcome of Patients With Implantation of Second-Generation Drug-Eluting Stents in the Right Coronary Ostium in the TWENTE Trial

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Bare Metal and Drug-Eluting Stents: Devices, Indications, and Outcomes

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

Drug-Eluting Stents: Past, Present, and Future

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Left Main Restenosis: Incidence, Implications, and Management

Dedicated Bifurcation Stents in Left Main Disease: Do the Data Support Their Need?

Bioresorbable Scaffolds in Left Main PCI: Technique Considerations and Outcomes

Are There Meaningful Differences Between Metallic DES in Left Main PCI?

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

TCT-50. Angiographic Predictor of 2-Year Stent Thrombosis in Patients Receiving Drug-eluting Stents: Insights from the ADAPT-DES Study

Biodegradable-Polymer Drug-Eluting Stents versus Bare Metal Stents versus Durable-Polymer Drug-Eluting Stents : A Systematic Review and Bayesian Approach Network Meta-Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content